



20 April 2022

Clinical Trial Results; No Subjects Enrolled in UK or EU/EEA

EudraCT: 2018-003093-27

To whom it may concern,

On behalf of the Sponsor, GB002, Inc., we wish to notify you that, for the clinical trial described below, although a EudraCT number was assigned and MHRA approval was granted (MHRA ref; 55555-0001-001), no subjects were enrolled in the United Kingdom or European Union.

Furthermore, this investigational medicinal product (seralutinib, also known as GB002) does not have a marketing authorization in the EU/UK and is not the subject of any ongoing MAA procedure.

Therefore, GB002, Inc. will not be submitting study results to EudraCT for the study described below.

| EudraCT number | Sponsor code | Title |
|----------------|--------------|---|
| 2018-003093-27 | GB002-1101 | A Phase 1b, Randomized, Subject- And Investigator Blinded, Placebo-Controlled, Multi-Center Clinical Trial to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Biomarkers of Inhaled Gb002 in Subjects with WHO Group 1 Pulmonary Arterial Hypertension (PAH) |

Please contact me if you require any additional information.

Yours sincerely,

Conor O'Donovan

Executive Director, Regulatory Affairs

Gossamer Bio 002 Limited, on behalf of GB002, Inc.

+353-1-526-9881

regaffairs@gossamerbio.com